Mark J. Ginski

Mark J. Ginski, Ph.D. is a successful biopharma executive leader with over 25 years of broad CMC experience spanning preclinical and clinical development through commercial manufacturing of both drug substance and drug product for small molecules, peptides and biologics. Dr. Ginski has extensive experience with all aspects of CMC and has over two decades of experience with successful management of outsourced CMC activities with both contract research organizations (CROs) and contract manufacturing organizations (CMOs). Prior to joining VistaGen, he served as Vice President, Product Development for ANI Pharmaceuticals and as Senior Director, CMC and Operations, Autoimmune and Rare Diseases for Questcor Pharmaceuticals/Mallinckrodt Pharmaceuticals. Dr. Ginski has previously held various leadership positions with Guilford Pharmaceuticals, Shire Pharmaceuticals, Alba Therapeutics. In addition, Dr. Ginski co-founded Fell Laboratories in 2011, whose only asset was acquired by Cerecor in 2012. Dr. Ginski holds a B.S. in Biological Sciences from the University of Maryland and received his Ph.D. in Pharmaceutical Studies from the University of Maryland School of Pharmacy.